title: Olanzapine, quetiapine, and risperidone: long-term effects on monoamine transporters in rat forebrain.
abstract: Long-term effects of novel atypical antipsychotic drugs on monoamine transporters are unknown. We compared labeling of dopamine (DAT) and serotonin (SERT) transporter proteins in subregions of rat corpus striatum by quantitative autoradiography with [(3)H]2-beta-carbomethoxy-3-beta-[4'-iodophenyl]tropane ([(3)H]beta-CIT) and [(3)H]paroxetine after 28 days of continuous subcutaneous infusion of olanzapine, quetiapine, risperidone, or vehicle controls. Drug treatment did not significantly alter the abundance of either transporter type in caudate-putamen or nucleus accumbens, indicating that transporter proteins required to inactivate synaptically released dopamine and serotonin resist adaptations to long-term treatment with novel antipsychotics that affect neurotransmission by these amines.
authors.affiliation: Mailman Research Center, McLean Division of Massachusetts General Hospital, Belmont, MA 02478, USA. ftarazi@hms.harvard.edu
authors.forename: F I
authors.initials: FI
authors.lastname: Tarazi
authors.forename: K
authors.initials: K
authors.lastname: Zhang
authors.forename: R J
authors.initials: RJ
authors.lastname: Baldessarini
mesh_terms: D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology*; D001345:Autoradiography; D001569:Benzodiazepines; D002352:Carrier Proteins / Q000032:analysis*; D002421:Caudate Nucleus / Q000737:chemistry / Q000187:drug effects; D003042:Cocaine / Q000031:analogs & derivatives / Q000378:metabolism / Q000494:pharmacology; D003987:Dibenzothiazepines / Q000494:pharmacology*; D050483:Dopamine Plasma Membrane Transport Proteins; D008297:Male; D008562:Membrane Glycoproteins / Q000032:analysis; D026901:Membrane Transport Proteins; D009419:Nerve Tissue Proteins; D009714:Nucleus Accumbens / Q000737:chemistry / Q000187:drug effects; D000077152:Olanzapine; D017374:Paroxetine / Q000378:metabolism / Q000494:pharmacology; D010890:Pirenzepine / Q000031:analogs & derivatives* / Q000494:pharmacology; D016548:Prosencephalon / Q000737:chemistry / Q000187:drug effects*; D011699:Putamen / Q000737:chemistry / Q000187:drug effects; D000069348:Quetiapine Fumarate; D011869:Radioligand Assay; D051381:Rats; D017207:Rats, Sprague-Dawley; D018967:Risperidone / Q000494:pharmacology*; D050486:Serotonin Plasma Membrane Transport Proteins; D017367:Selective Serotonin Reuptake Inhibitors / Q000378:metabolism / Q000494:pharmacology; D014316:Tritium
chemical_list: D014150:Antipsychotic Agents; D001569:Benzodiazepines; D002352:Carrier Proteins; D003042:Cocaine; D003987:Dibenzothiazepines; D050483:Dopamine Plasma Membrane Transport Proteins; D008562:Membrane Glycoproteins; D026901:Membrane Transport Proteins; D009419:Nerve Tissue Proteins; D000077152:Olanzapine; D017374:Paroxetine; D010890:Pirenzepine; D000069348:Quetiapine Fumarate; D018967:Risperidone; D050486:Serotonin Plasma Membrane Transport Proteins; D017367:Selective Serotonin Reuptake Inhibitors; D014316:Tritium; C493216:Slc6a3 protein, rat; C493232:Slc6a4 protein, rat; C069723:2beta-carbomethoxy-3beta-(4-iodophenyl)tropane